Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.
Oncoimmunology
; 3: e28610, 2014.
Article
em En
| MEDLINE
| ID: mdl-25097801
ABSTRACT
Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncoimmunology
Ano de publicação:
2014
Tipo de documento:
Article